— Know what they know.
Not Investment Advice

NAUT NASDAQ

Nautilus Biotechnolgy, Inc.
1W: +103.6% 1M: +103.8% 3M: +13.9% YTD: +2.6% 1Y: +134.7% 3Y: -38.9% 5Y: -70.4%
$1.96
+0.39 (+24.84%)
 
Weekly Expected Move ±23.0%
$1 $2 $2 $2 $3
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 63 · $249.4M mcap · 56M float · 2.46% daily turnover · Short 50% of daily vol

Balance Sheet Trends

Total Assets
$191M -21.3% ▼
5Y CAGR: +17.6%
Total Liabilities
$34M +0.4% ▲
5Y CAGR: -21.5%
Shareholders Equity
$157M -24.8% ▼
Cash & Investments
$103M -20.4% ▼
5Y CAGR: +6.1%
Total Debt
$30M -1.5% ▼
5Y CAGR: +44.4%
Net Debt
$18M +522.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$186M$115M$19M$28M$12M
Short-Term Investments$160M$70M$154M$102M$91M
Cash & ST Investments$346M$184M$173M$130M$103M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$3M$3M$3M
Total Current Assets$349M$187M$177M$133M$106M
Property, Plant & Equip.$32M$33M$37M$32M$31M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$16M$129M$91M$76M$53M
Other Non-Current Assets$997K$1M$1M$1M$1M
Total Non-Current Assets$49M$163M$129M$110M$85M
Total Assets$398M$350M$306M$243M$191M
— Liabilities —
Accounts Payable$2M$1M$2M$987K$943K
Short-Term Debt$0$0$0$0$4M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$388K$438K$3M$3M$3M
Total Current Liabilities$6M$7M$9M$8M$8M
Long-Term Debt$0$0$0$0$26M
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$29M$28M$31M$26M$26M
Total Liabilities$35M$35M$40M$34M$34M
— Equity —
Common Stock$12K$12K$13K$13K$13K
Retained Earnings-$81M-$139M-$202M-$273M-$332M
Accumulated OCI-$184K-$2M-$255K$57K$243K
Total Stockholders Equity$364M$315M$265M$209M$157M
Total Liabilities & Equity$398M$350M$306M$243M$191M
— Key Metrics —
Total Debt$30M$30M$35M$30M$30M
Net Debt-$156M-$84M$15M$3M$18M
Total Investments$176M$199M$245M$179M$144M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms